Indications
Zyclara is indicated for the topical treatment of clinically typical, non-hyperkeratotic, non-hypertrophic, visible or palpable actinic keratosis of the full face or balding scalp in immunocompetent adults when other topical treatment options are contraindicated or less appropriate.
Composition
- Active substance
- imiquimod
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Zyclara
- Active substance
- imiquimod
- ATC code
- D06BB10
- Group
- Dermatologicals
- Therapeutic area
- Keratosis, Keratosis, Actinic
- Marketing authorisation holder
- Viatris Healthcare Limited
- Status
- Authorised